company background image
PHAR

Pharming GroupNasdaqGM:PHAR Stock Report

Market Cap

€636.9m

7D

1.9%

1Y

n/a

Updated

23 Sep, 2021

Data

Company Financials +
PHAR fundamental analysis
Snowflake Score
Valuation3/6
Future Growth5/6
Past Performance2/6
Financial Health5/6
Dividends0/6

PHAR Overview

Pharming Group N.V., a specialty pharmaceutical company, develops products for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally.

Pharming Group Competitors

BioCryst Pharmaceuticals

NasdaqGS:BCRX

US$2.8b

KalVista Pharmaceuticals

NasdaqGM:KALV

US$454.5m

CSL

ASX:CSL

AU$142.2b

Takeda Pharmaceutical

TSE:4502

JP¥5.9t

Price History & Performance

Summary of all time highs, changes and price drops for Pharming Group
Historical stock prices
Current Share Price€9.90
52 Week High€9.43
52 Week Low€21.99
Beta1.68
1 Month Change-2.75%
3 Month Change-15.57%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-40.72%

Recent News & Updates

Shareholder Returns

PHARUS BiotechsUS Market
7D1.9%0.07%-0.5%
1Yn/a31.0%37.5%

Return vs Industry: Insufficient data to determine how PHAR performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how PHAR performed against the US Market.

Price Volatility

Is PHAR's price volatile compared to industry and market?
PHAR volatility
PHAR Beta1.68
Industry Beta1.03
Market Beta1

Stable Share Price: PHAR is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: PHAR's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a262Simon de Vrieshttps://www.pharming.com

Pharming Group N.V., a specialty pharmaceutical company, develops products for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company’s lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre- eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases.

Pharming Group Fundamentals Summary

How do Pharming Group's earnings and revenue compare to its market cap?
PHAR fundamental statistics
Market Cap€542.74m
Earnings (TTM)€26.79m
Revenue (TTM)€174.41m

20.3x

P/E Ratio

3.1x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PHAR income statement (TTM)
Revenue€174.41m
Cost of Revenue€18.61m
Gross Profit€155.80m
Expenses€129.01m
Earnings€26.79m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

Oct 28, 2021

Earnings per share (EPS)0.042
Gross Margin89.33%
Net Profit Margin15.36%
Debt/Equity Ratio74.4%

How did PHAR perform over the long term?

See historical performance and comparison

Valuation

Is Pharming Group undervalued compared to its fair value and its price relative to the market?

2.4%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: PHAR ($9.9) is trading below our estimate of fair value ($10.14)

Significantly Below Fair Value: PHAR is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: PHAR is good value based on its PE Ratio (20.3x) compared to the US Biotechs industry average (25.1x).

PE vs Market: PHAR is poor value based on its PE Ratio (20.3x) compared to the US market (17.7x).


Price to Earnings Growth Ratio

PEG Ratio: PHAR is good value based on its PEG Ratio (0.6x)


Price to Book Ratio

PB vs Industry: PHAR's PB Ratio (3.3x) is in line with the US Biotechs industry average.


Future Growth

How is Pharming Group forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

34.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PHAR's forecast earnings growth (34.8% per year) is above the savings rate (2%).

Earnings vs Market: PHAR's earnings (34.8% per year) are forecast to grow faster than the US market (14.9% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: PHAR's revenue (23.2% per year) is forecast to grow faster than the US market (9.8% per year).

High Growth Revenue: PHAR's revenue (23.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if PHAR's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Pharming Group performed over the past 5 years?

52.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PHAR has high quality earnings.

Growing Profit Margin: PHAR's current net profit margins (15.4%) are lower than last year (22.7%).


Past Earnings Growth Analysis

Earnings Trend: PHAR has become profitable over the past 5 years, growing earnings by 52.9% per year.

Accelerating Growth: PHAR's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: PHAR had negative earnings growth (-34.2%) over the past year, making it difficult to compare to the Biotechs industry average (4.9%).


Return on Equity

High ROE: PHAR's Return on Equity (16.1%) is considered low.


Financial Health

How is Pharming Group's financial position?


Financial Position Analysis

Short Term Liabilities: PHAR's short term assets (€211.1M) exceed its short term liabilities (€40.2M).

Long Term Liabilities: PHAR's short term assets (€211.1M) exceed its long term liabilities (€139.5M).


Debt to Equity History and Analysis

Debt Level: PHAR's debt to equity ratio (74.4%) is considered high.

Reducing Debt: PHAR's debt to equity ratio has reduced from 82.2% to 74.4% over the past 5 years.

Debt Coverage: PHAR's debt is well covered by operating cash flow (37.9%).

Interest Coverage: PHAR earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Pharming Group current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate PHAR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PHAR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PHAR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PHAR's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PHAR's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.8yrs

Average management tenure


CEO

Simon de Vries (62 yo)

12.83yrs

Tenure

€2,563,000

Compensation

Dr. Sijmen De Vries, also known as Simon, M.D., M.B.A., has been the Chief Executive Officer of Pharming Group NV since November 3, 2008 and also serves as its Executive Director. He serves as President at...


CEO Compensation Analysis

Compensation vs Market: Simon's total compensation ($USD3.01M) is about average for companies of similar size in the US market ($USD2.35M).

Compensation vs Earnings: Simon's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.


Leadership Team

Experienced Management: PHAR's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.


Board Members

Experienced Board: PHAR's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Pharming Group N.V.'s employee growth, exchange listings and data sources


Key Information

  • Name: Pharming Group N.V.
  • Ticker: PHAR
  • Exchange: NasdaqGM
  • Founded: NaN
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €542.744m
  • Listing Market Cap: €636.948m
  • Shares outstanding: 646.12m
  • Website: https://www.pharming.com

Number of Employees


Location

  • Pharming Group N.V.
  • Darwinweg 24
  • Leiden
  • Zuid-Holland
  • 2333 CR
  • Netherlands

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/23 22:54
End of Day Share Price2021/09/23 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.